ESLAW — Estrella Immunopharma, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1844417 ·
Last close
$0.06
Market Cap
—
52W High
$0.06
52W Low
$0.06
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,084,247 | -2,306,339 | 1,824,681 | 146,670 | 9,256,014 |
| Mar 2026 | 0 | — | -2,292,064 | -2,292,064 | 3,657,198 | 1,927,404 | 8,927,494 |
| Dec 2025 | 0 | — | -613,199 | -613,174 | 3,176,975 | 1,384,302 | 13,543,033 |
| Sep 2025 | 0 | — | -4,801,149 | -4,801,149 | 3,523,511 | 1,626,610 | 13,359,934 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,017,708
Investing CF
—
Financing CF
$9,523,639
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-39,282,879
Inventory
—
Receivables
$229,794
ST Investments
—
EBIT TTM
$-13,250,440
Pretax Income TTM
$-13,250,440
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,062,674 | -13,063,512 | 3,176,975 | 13,543,033 | -10,366,058 | -1,785,679 |
| Jun 2024 | 0 | -7,310,098 | -7,311,723 | 4,454,189 | 180,701 | 4,273,488 | -16,068,306 |
| Jun 2023 | 0 | -11,114,402 | -11,114,402 | 3,028,399 | 14,770,949 | -11,742,550 | -1,336,121 |
| Jun 2022 | 0 | -1,685,347 | -1,685,347 | 4,921,666 | 5,961,509 | -1,039,843 | -1,442,028 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $226.05B | $418.13 | — |
| GILD | GILEAD SCIENCES, INC. | $188.73B | $152.21 | — |
| MRNA | Moderna, Inc. | $78.76B | $197.28 | — |
| ARGX | ARGENX SE | $60.46B | $972.25 | — |
| RVMD | Revolution Medicines, Inc. | $43.24B | $201.74 | — |
News headlines (Yahoo Finance, 1h cache)
ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial
2026-08-26 12:42 · Yahoo
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-08-11 12:00 · Yahoo
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-08-03 12:00 · Yahoo
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
2026-07-29 12:00 · Yahoo
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
2026-07-24 12:00 · Yahoo
ESLA: Can Next-Generation CAR-T Therapy Improve Disease Control in Extranodal Lymphoma?
2026-07-14 10:22 · Yahoo
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
2026-03-18 09:20 · Yahoo
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL
2026-02-09 14:02 · Yahoo
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?
2025-11-04 17:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.